Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with <i>AKT1</i> E17K-Mutant, ER-Positive Metastatic Breast Cancer

Lillian M. Smyth, Kenji Tamura, Mafalda Oliveira, Eva M. Ciruelos, Ingrid A. Mayer, Marie-Paule Sablin, Laura Biganzoli, Helen J. Ambrose, Jack Ashton, Alan Barnicle, Des D. Cashell, Claire Corcoran, Elza C. de Bruin, Andrew Foxley, Joana Hauser, Justin P.O. Lindemann, Rhiannon Maudsley, Robert McEwen, Michele Moschetta, Martin Pass, Vicky Rowlands, Gaia Schiavon, Udai Banerji, Maurizio Scaltriti, Barry S. Taylor, Sarat Chandarlapaty, José Baselga, David M. Hyman

Open source

DOI: 10.1158/1078-0432.ccr-19-3953
Published: 2020-08-01
Container: Clinical Cancer Research
Publisher: American Association for Cancer Research (AACR)
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1158/1078-0432.ccr-19-3953,
  title = {Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with
                    <i>AKT1</i>
                    E17K-Mutant, ER-Positive Metastatic Breast Cancer},
  author = {Lillian M. Smyth and Kenji Tamura and Mafalda Oliveira and Eva M. Ciruelos and Ingrid A. Mayer and Marie-Paule Sablin and Laura Biganzoli and Helen J. Ambrose and Jack Ashton and Alan Barnicle and Des D. Cashell and Claire Corcoran and Elza C. de Bruin and Andrew Foxley and Joana Hauser and Justin P.O. Lindemann and Rhiannon Maudsley and Robert McEwen and Michele Moschetta and Martin Pass and Vicky Rowlands and Gaia Schiavon and Udai Banerji and Maurizio Scaltriti and Barry S. Taylor and Sarat Chandarlapaty and José Baselga and David M. Hyman},
  year = {2020},
  journal = {Clinical Cancer Research},
  doi = {10.1158/1078-0432.ccr-19-3953},
  url = {https://doi.org/10.1158/1078-0432.ccr-19-3953}
}

RIS

TY  - JOUR
TI  - Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with
                    <i>AKT1</i>
                    E17K-Mutant, ER-Positive Metastatic Breast Cancer
AU  - Lillian M. Smyth
AU  - Kenji Tamura
AU  - Mafalda Oliveira
AU  - Eva M. Ciruelos
AU  - Ingrid A. Mayer
AU  - Marie-Paule Sablin
AU  - Laura Biganzoli
AU  - Helen J. Ambrose
AU  - Jack Ashton
AU  - Alan Barnicle
AU  - Des D. Cashell
AU  - Claire Corcoran
AU  - Elza C. de Bruin
AU  - Andrew Foxley
AU  - Joana Hauser
AU  - Justin P.O. Lindemann
AU  - Rhiannon Maudsley
AU  - Robert McEwen
AU  - Michele Moschetta
AU  - Martin Pass
AU  - Vicky Rowlands
AU  - Gaia Schiavon
AU  - Udai Banerji
AU  - Maurizio Scaltriti
AU  - Barry S. Taylor
AU  - Sarat Chandarlapaty
AU  - José Baselga
AU  - David M. Hyman
PY  - 2020
JO  - Clinical Cancer Research
DO  - 10.1158/1078-0432.ccr-19-3953
UR  - https://doi.org/10.1158/1078-0432.ccr-19-3953
ER  -

APA

Smyth, L. M., Tamura, K., Oliveira, M., Ciruelos, E. M., Mayer, I. A., Sablin, M., Biganzoli, L., Ambrose, H. J., Ashton, J., Barnicle, A., Cashell, D. D., Corcoran, C., Bruin, E. C. D., Foxley, A., Hauser, J., Lindemann, J. P., Maudsley, R., McEwen, R., Moschetta, M., Pass, M., Rowlands, V., Schiavon, G., Banerji, U., Scaltriti, M., Taylor, B. S., Chandarlapaty, S., Baselga, J., & Hyman, D. M. (2020). Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with <i>AKT1</i> E17K-Mutant, ER-Positive Metastatic Breast Cancer. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-19-3953

Source records

crossref · retrieved 2026-09-27T06:24:40.263Z